Journal ArticleDOI
Cannabinoids in treatment-resistant epilepsy: A review.
TLDR
Open-label studies with 100mg/ml CBD have provided additional evidence of its efficacy along with an adequate safety profile in children and young adults with a spectrum of TREs and Phase 3 RCTs with Epidiolex support efficacy and adequate safety profiles for children with DS and LGS.About:
This article is published in Epilepsy & Behavior.The article was published on 2017-05-01. It has received 162 citations till now. The article focuses on the topics: Cannabis & Cannabidiol.read more
Citations
More filters
Journal ArticleDOI
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Orrin Devinsky,Anup D. Patel,Elizabeth A. Thiele,Matthew Wong,Richard Appleton,Cynthia L. Harden,Sam M. Greenwood,Gilmour Morrison,Kenneth Sommerville +8 more
TL;DR: This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.
Journal ArticleDOI
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.
TL;DR: With the legalization of marijuana for medicinal purposes and/or recreational use in many countries, physicians should be alert to the possibility that the use of marijuana or its potent synthetic analogues might be the underlying cause of severe cardiovascular events and pathologies.
Journal ArticleDOI
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
TL;DR: There is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes, for the first time, according to currently available information.
Journal ArticleDOI
A Cross-Sectional Study of Cannabidiol Users
Jamie Corroon,Joy A. Phillips +1 more
TL;DR: Consumers are using CBD as a specific therapy for multiple diverse medical conditions—particularly pain, anxiety, depression, and sleep disorders, and these data provide a compelling rationale for further research to better understand the therapeutic potential of CBD.
Journal ArticleDOI
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.
TL;DR: Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC, as well as other cannabinoid molecules currently being evaluated for medicinal purposes, separately and in combination.
References
More filters
Journal ArticleDOI
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
TL;DR: Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.
Journal ArticleDOI
Long-term mortality in childhood-onset epilepsy.
Matti Sillanpää,Shlomo Shinnar +1 more
TL;DR: In this article, the authors report on long-term mortality in a Finnish cohort of subjects with a diagnosis of epilepsy in childhood, which was prospectively followed for 40 years and found that the risk of sudden, unexplained death was especially high among children who were not in remission.
Journal ArticleDOI
Nonadherence to antiepileptic drugs and increased mortality. Findings from the RANSOM Study
TL;DR: It is suggested that nonadherence to antiepileptic drugs can have serious or fatal consequences for patients with epilepsy.
Journal ArticleDOI
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
TL;DR: It is shown that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy, and objective measurements of a standardized preparation of pure cannABidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures.
Journal ArticleDOI
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
TL;DR: Rufinamide was an effective and well-tolerated treatment for seizures associated with Lennox–Gastaut syndrome and had a greater improvement in seizure severity than placebo.
Related Papers (5)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky,Eric D. Marsh,Daniel Friedman,Elizabeth A. Thiele,Linda Laux,Joseph Sullivan,Ian Miller,Robert Flamini,Angus Wilfong,Francis Filloux,Matthew Wong,Nicole Tilton,Patricia L. Bruno,Judith Bluvstein,Julie Hedlund,Rebecca M. Kamens,Jane Maclean,Srishti Nangia,Nilika S. Singhal,Carey A Wilson,Anup D. Patel,Maria Roberta Cilio +21 more
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele,Eric D. Marsh,Jacqueline A French,Maria Mazurkiewicz-Bełdzińska,Selim R Benbadis,Charuta Joshi,Paul D Lyons,Adam Taylor,Claire Roberts,Kenneth W. Sommerville,Kenneth W. Sommerville,Boudewjin Gunning,Jacek Gawlowicz,Pawel Lisewski,Maria Mazurkiewicz Beldzinska,Krystyna Mitosek Szewczyk,Barbara Steinborn,Marta Zolnowska,Elaine Hughes,Ailsa McLellan,Selim R. Benbadis,Michael A. Ciliberto,Gary G. Clark,Dennis J. Dlugos,Francis Filloux,Robert Flamini,Jacqueline A. French,Michael Frost,Sheryl R. Haut,Siddarth Kapoor,Sudha Kilaru Kessler,Linda Laux,Paul D. Lyons,Eric D. Marsh,David Moore,Richard P. Morse,Venkatesh Nagaraddi,William E. Rosenfeld,Laurie E. Seltzer,Renée A. Shellhaas,Joseph Sullivan,Elizabeth A. Thiele,Liu Lin Thio,David Wang,Angus A. Wilfong +44 more